Tg Therapeutics (TGTX) FCF Margin (2017 - 2026)
Tg Therapeutics (TGTX) recorded quarterly FCF Margin of 8.76% in Q1 2026, down 186.07% quarter-over-quarter from 10.17% in Q4 2025, and up 1502.0% on a YoY basis from 0.55% in Q1 2025.
Tg Therapeutics (TGTX) FCF Margin (2017 - 2026) Analysis & Trends
Tg Therapeutics' FCF Margin history runs 10 years deep, the most recent figure standing at 8.76% for Q1 2026.
- In Q1 2026, FCF Margin rose 1502.0% year-over-year to 8.76%; the TTM figure through Mar 2026 stood at 2.03% (up 1379.0% YoY), while the FY2025 annual figure was 4.05%, up 827.0% from the prior year.
- FCF Margin was 8.76% for Q1 2026 at Tg Therapeutics, down from 10.17% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 50.48% in Q3 2023 to a low of 36701.06% in Q3 2022.
- Historically, FCF Margin has averaged 4664.84% across 5 years, with a median of 23.72% in 2024.
- The sharpest annual moves came in 2022 and 2023: FCF Margin tumbled 3338678 bps in 2022, then surged 3675154 bps in 2023.
- A 5-year view of FCF Margin shows it stood at 29841.25% in 2022, then soared by 100 bps to 30.04% in 2023, then rose by 21 bps to 23.72% in 2024, then jumped by 143 bps to 10.17% in 2025, then sank by 186 bps to 8.76% in 2026.
- The last three FCF Margin figures came in at 8.76% (Q1 2026), 10.17% (Q4 2025), and 14.37% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tg Therapeutics | 7.71 Bn | 7.06 Bn | 171.41 Mn | -8.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.76% |
| Dec 31, 2025 | 10.17% |
| Sep 30, 2025 | -14.37% |
| Jun 30, 2025 | 5.24% |
| Mar 31, 2025 | -23.78% |
| Dec 31, 2024 | -23.72% |
| Sep 30, 2024 | -14.58% |
| Jun 30, 2024 | 7.54% |
| Mar 31, 2024 | -12.93% |
| Dec 31, 2023 | -30.04% |
| Sep 30, 2023 | 50.48% |
| Jun 30, 2023 | -261.32% |
| Mar 31, 2023 | -767.68% |
| Dec 31, 2022 | -29,841.25% |
| Sep 30, 2022 | -36,701.06% |
| Jun 30, 2022 | -8,268.69% |
| Mar 31, 2022 | -3,407.54% |
| Dec 31, 2021 | -3,747.91% |
| Sep 30, 2021 | -3,314.29% |
| Jun 30, 2021 | -3,905.76% |